These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37359941)

  • 21. Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution.
    Kow AW; Kwon CH; Song S; Kim JM; Joh JW
    Surgery; 2015 Apr; 157(4):645-53. PubMed ID: 25794626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
    Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastric cancer with peritoneal metastases: Efficiency of standard treatment methods.
    Yarema R; Оhorchak М; Hyrya P; Kovalchuk Y; Safiyan V; Karelin I; Ferneza S; Fetsych M; Matusyak M; Oliynyk Y; Fetsych Т
    World J Gastrointest Oncol; 2020 May; 12(5):569-581. PubMed ID: 32461788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time trends in survival from cancer of unknown primary: small steps forward.
    Riihimäki M; Hemminki A; Sundquist K; Hemminki K
    Eur J Cancer; 2013 Jul; 49(10):2403-10. PubMed ID: 23518210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.
    Shaw PH; Adams R; Jordan C; Crosby TD
    Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):87-95. PubMed ID: 17305260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.
    Riihimäki M; Thomsen H; Hemminki A; Sundquist K; Hemminki K
    BMC Cancer; 2013 Jan; 13():36. PubMed ID: 23356713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait.
    Huey RW; Smaglo BG; Estrella JS; Matamoros A; Overman MJ; Varadhachary GR; Raghav KPS
    Oncologist; 2021 Apr; 26(4):e650-e657. PubMed ID: 33524217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
    Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study.
    Vos M; Ho VKY; Oosten AW; Verhoef C; Sleijfer S
    Oncologist; 2019 Jul; 24(7):e526-e535. PubMed ID: 30190301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of metachronous peritoneal metastases in patients with pT4a versus pT4b colon cancer: An international multicentre cohort study.
    Bastiaenen VP; Aalbers AGJ; Arjona-Sánchez A; Bellato V; van der Bilt JDW; D'Hoore AD; Espinosa-Redondo E; Klaver CEL; Nagtegaal ID; van Ramshorst B; van Santvoort HC; Sica GS; Snaebjornsson P; Wasmann KATGM; de Wilt JHW; Wolthuis AM; Tanis PJ
    Eur J Surg Oncol; 2021 Sep; 47(9):2405-2413. PubMed ID: 34030920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment and Survival Outcomes for Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study.
    Dietz MV; Ziekman MJ; van Kooten JP; Brandt-Kerkhof ARM; van Meerten E; Verhoef C; Madsen EVE
    Ann Surg Oncol; 2023 Apr; 30(4):2048-2056. PubMed ID: 36566258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, Treatment, and Survival of Synchronous Peritoneal Metastases in Pancreatic Cancer: Update of a Nationwide Cohort.
    Rijken A; Bakkers C; van Erning FN; van der Geest LG; de Vos-Geelen J; Besselink MG; Lemmens VE; de Hingh IHJT;
    Pancreas; 2021 Jul; 50(6):827-833. PubMed ID: 34347730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival outcomes following craniotomy for intracranial metastases from an unknown primary.
    Gough M; Nielsen M; Coulter IC; Holliman D
    Int J Clin Oncol; 2020 Aug; 25(8):1475-1482. PubMed ID: 32358736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peritoneal metastases from extra-abdominal cancer - A population-based study.
    Flanagan M; Solon J; Chang KH; Deady S; Moran B; Cahill R; Shields C; Mulsow J
    Eur J Surg Oncol; 2018 Nov; 44(11):1811-1817. PubMed ID: 30139510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Prognostic for Peritoneal Metastases from Colorectal Cancer Treated with Surgery.
    Chen C; Wang J; Zhao Y; Ge X; Wang Z; Yu S; Song Y; Ding K; Zhang S; Zheng S; Sun L
    Cancer Manag Res; 2020; 12():10587-10602. PubMed ID: 33149668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer.
    van Gestel YR; Thomassen I; Lemmens VE; Pruijt JF; van Herk-Sukel MP; Rutten HJ; Creemers GJ; de Hingh IH
    Eur J Surg Oncol; 2014 Aug; 40(8):963-9. PubMed ID: 24183168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer.
    Mendoza-Moreno F; Diez-Alonso M; Matías-García B; Ovejero-Merino E; Gómez-Sanz R; Blázquez-Martín A; Quiroga-Valcárcel A; Vera-Mansilla C; Molina R; San-Juan A; Barrena-Blázquez S; Ortega MA; Alvarez-Mon M; Gutiérrez-Calvo A
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival in cancer of unknown primary site: population-based analysis by site and histology.
    Hemminki K; Bevier M; Hemminki A; Sundquist J
    Ann Oncol; 2012 Jul; 23(7):1854-63. PubMed ID: 22115926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma.
    Dietz MV; van Kooten JP; Said I; Brandt-Kerkhof ARM; Verhoef C; Bremers AJA; de Wilt JHW; de Reuver PR; Madsen EVE
    Ann Surg Oncol; 2022 Oct; 29(11):6566-6576. PubMed ID: 35513588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.